CD8A and neoplasm: As potential mechanisms for higher adverse event rates after CRT to ICIs, we considered the following hypotheses: CRT remodels the tumor microenvironment with increased CD8+ T-cell infiltration[20]; tumor immune escape may be accompanied by an expanded exhausted T-cell compartment[21]; and ICIs administration may reinvigorate exhausted T cells, enhancing antitumor activity, but also potentially increasing immune-mediated toxicities.